AR045180A1 - Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos - Google Patents

Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos

Info

Publication number
AR045180A1
AR045180A1 ARP040102725A ARP040102725A AR045180A1 AR 045180 A1 AR045180 A1 AR 045180A1 AR P040102725 A ARP040102725 A AR P040102725A AR P040102725 A ARP040102725 A AR P040102725A AR 045180 A1 AR045180 A1 AR 045180A1
Authority
AR
Argentina
Prior art keywords
hydrogen
formula
integer
alkyl
amino
Prior art date
Application number
ARP040102725A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045180A1 publication Critical patent/AR045180A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se describen el uso de compuestos de 3-amino cromano y 2-amino tetralina y composiciones que contienen dichos compuestos para el tratamiento de desórdenes de serotonina, tales como depresión y ansiedad. Reivindicación 1: Un compuesto de fórmula (1), o un profármaco, un estereoisómero o una sal farmacéuticamente aceptable del mismo, donde: X es O o CH2; R1 es hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, aralquilo u oxetano; R2 es -(CH2)a-R5, M, o un resto de grupo de fórmula (2), donde a es un número entero de 2 a 4 y R5 es A, B, C, D, K, L o U; a es un número entero de 2 y R5 es E, G o J; a es un número entero de 3 o 4 y R5 es P; A es una fórmula (3); B es una fórmula (4); C es una fórmula (5); D es una fórmula (6); E es una fórmula (7); G es una fórmula (8); J es una fórmula (9); K es una fórmula (10); L es una fórmula (11); M es un grupo de fórmulas (12); Z es un grupo de fórmulas (13); P es una fórmula (14); U es una fórmula (15); R3 es -OCH3, -COR12, - SO2NR13R14, o un heterociclo; R4 es hidrógeno o halo; R6 es hidrógeno o alquilo; R7 es hidrógeno, flúor, cloro, ciano o alcoxi en cualquiera de las posiciones 4-, 5-, 6-, o 7; R8 es hidrógeno, halo, alcoxi C1-3 o alquilo C1-3; R9 es hidrógeno, halo, alcoxi C1-3 o alquilo C1-3; R10 es hidrógeno y R11 es metilo; o R10 y R11 son metilo; R12 es alquilo C1-4, alcoxi o NR13R14; R13 y R14 son independientemente hidrógeno, alquilo, cicloalquilo, metilciclopropilo, fenilo, o bencilo; R19 y R20 son independientemente hidrógeno, flúor, cloro, ciano, o alquilo C1-6 en cualquiera de las posiciones 5-, 6-, 7-, u 8-; R21 es hidrógeno o flúor en cualquiera de las posiciones 4-, 5-, 6-, o 7-; R22 es un anillo de 3- a 7- miembros; n es un número entero de 1 a 2; Y es O, S, o NH; donde, cuando Y es O, entonces R16 es hidrógeno; R17 es hidrógeno o OCH3; R18 es hidrógeno; y d es un número entero de 2 a 3; cuando Y es S, entonces R16 es hidrógeno o hidroxilo; R17 es hidrógeno; R18 es hidrógeno o flúor; y d es un número entero de 2; cuando Y es NH, entonces R16 es ceto o metilo; R17 es hidrógeno; R18 es flúor; y d es un número entero de 2.
ARP040102725A 2003-07-30 2004-07-30 Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos AR045180A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49113703P 2003-07-30 2003-07-30
US49179403P 2003-08-01 2003-08-01
US10/898,866 US20050032873A1 (en) 2003-07-30 2004-07-26 3-Amino chroman and 2-amino tetralin derivatives

Publications (1)

Publication Number Publication Date
AR045180A1 true AR045180A1 (es) 2005-10-19

Family

ID=34119805

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102725A AR045180A1 (es) 2003-07-30 2004-07-30 Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos

Country Status (15)

Country Link
US (1) US20050032873A1 (es)
EP (1) EP1651637A1 (es)
JP (1) JP2007500718A (es)
KR (1) KR20060054376A (es)
AR (1) AR045180A1 (es)
AU (1) AU2004261649A1 (es)
BR (1) BRPI0413022A (es)
CA (1) CA2533363A1 (es)
CR (1) CR8191A (es)
EC (1) ECSP066336A (es)
IL (1) IL173193A0 (es)
MX (1) MXPA06001008A (es)
NO (1) NO20060402L (es)
TW (1) TW200503705A (es)
WO (1) WO2005012291A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
ES2340180T3 (es) * 2004-06-01 2010-05-31 F.Hoffmann-La Roche Ag 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
WO2006089053A2 (en) * 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
MX2007011938A (es) 2005-03-28 2008-03-14 Toyama Chemical Co Ltd Proceso para produccion de 1-(3-(2-(1-benzotiofen-5-il)etoxi) propil) acetidin-3-ol or sales del mismo.
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
AU2006259294A1 (en) * 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
EP1996198A1 (en) * 2006-03-17 2008-12-03 Kalypsys, Inc. Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
US9724165B2 (en) 2006-05-19 2017-08-08 Mako Surgical Corp. System and method for verifying calibration of a surgical device
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
US20080221193A1 (en) * 2006-12-22 2008-09-11 Wyeth 3-amino chromane derivatives
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
CA2803083A1 (en) 2010-07-20 2012-01-26 Bayer Cropscience Ag Benzocycloalkenes as antifungal agents
MX343653B (es) 2010-12-17 2016-11-07 Rhodes Tech Síntesis de clorhidrato de metilfenidato a baja temperatura.
CN102746215A (zh) * 2011-04-18 2012-10-24 张兆勇 一种制备高纯度盐酸贝尼地平的方法
EP2874993B1 (de) 2012-07-20 2016-08-24 Bayer Pharma Aktiengesellschaft Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung
HUE030540T2 (en) 2012-07-20 2017-05-29 Bayer Pharma AG New 5-aminotetrahydroquinoline-2-carboxylic acids and their use
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
EP3137456B1 (en) 2014-04-29 2021-06-02 FMC Corporation Pyridazinone herbicides
EP3224261A4 (en) 2014-11-26 2018-05-16 The Trustees of Columbia University in the City of New York Opioid receptor modulators
CN108495849B (zh) 2015-10-28 2020-11-10 Fmc公司 哒嗪酮除草剂
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
JP2023530092A (ja) 2020-06-08 2023-07-13 タクトジェン インコーポレイテッド 精神障害又は精神高揚に有利なベンゾフラン組成物
WO2023107653A2 (en) * 2021-12-08 2023-06-15 Tactogen Inc Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3671544A (en) * 1970-07-13 1972-06-20 Warner Lambert Co 3,4,4a,9a-tetrahydro-2-(1h)carbazolones
US4235903A (en) * 1979-08-06 1980-11-25 American Home Products Corporation 1-Hydroxyalkanamine tetrahydrocarbazoles and cyclopent[b]indoles, compositions and method of use
US4319029A (en) * 1979-08-06 1982-03-09 American Home Products Corporation Hydroxyalkanamide tetrahydrocarbazoles
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
EP0254989B1 (en) * 1986-07-28 1990-09-26 Whitby Research Incorporated Substituted 2-aminotetralins
US5153225A (en) * 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5306830A (en) * 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
DE3919624A1 (de) * 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SE8904127D0 (sv) * 1989-12-07 1989-12-07 Astra Ab New biocyclic amino-substituted compounds
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5510374A (en) * 1990-04-09 1996-04-23 Adir Et Compagnie 3-aminochroman compounds
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
SE9701438D0 (sv) * 1997-04-17 1997-04-17 Astra Ab A new process
JPH1165435A (ja) * 1997-08-21 1999-03-05 Toyota Motor Corp 車両用地図データ処理装置
IL162243A0 (en) * 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
ECSP066336A (es) 2006-07-28
MXPA06001008A (es) 2006-04-11
US20050032873A1 (en) 2005-02-10
EP1651637A1 (en) 2006-05-03
CR8191A (es) 2006-07-14
WO2005012291A1 (en) 2005-02-10
IL173193A0 (en) 2006-06-11
BRPI0413022A (pt) 2006-10-03
NO20060402L (no) 2006-04-06
KR20060054376A (ko) 2006-05-22
CA2533363A1 (en) 2005-02-10
TW200503705A (en) 2005-02-01
AU2004261649A1 (en) 2005-02-10
JP2007500718A (ja) 2007-01-18

Similar Documents

Publication Publication Date Title
AR045180A1 (es) Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DE60208568D1 (de) Prostaglandinanaloga als ep4-rezeptoragonisten
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
DE602004031258D1 (de) Polycyclische mittel zur behandlung von infektione
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
HRP20070194T3 (en) N-thiazol-2-yl-benzamide derivatives
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ATE484502T1 (de) Neue verbindungen
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
SE0201937D0 (sv) Therapeutic agents
RU2007125660A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
WO2003008412A3 (en) Hetero-bicyclic crf antagonists

Legal Events

Date Code Title Description
FB Suspension of granting procedure